Early drug screening refers to the process of evaluating the biological activity, pharmacological effects, and medicinal value of substances (samples) that may be used as drugs using appropriate methods.

  Service scope：

Ø In vivo (in vitro) drug effectiveness screening, including enzyme, cell, organ, tissue and animal level

Ø Based on early pharmacokinetic screening, using ELISA, LC/MS, HPLC and other methods to screen the bioavailability and metabolic properties of early compounds

Ø Early toxicity screening, including high-throughput genetic toxicity, cardiac toxicity, and carcinogenicity screening, etc